Physical mapping of the DDX1 gene to 348 kb 5' of MYCN

Hiroshi Kuroda, Peter S. White, Erik P. Sulman, Chitra F. Manohar, Jill Reiter, Susan L. Cohn, Garrett M. Brodeur

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

One of the most important prognostic factors in neuroblastoma is amplification of the MYCN gene, which is strongly associated with advanced stages of disease and a poor prognosis. Although the MYCN amplicon sometimes spans more than 1 Mb, no other consistently expressed sequences from the MYCN amplicon have been reported. However, DDX1, a gene encoding a DEAD box: protein, was recently mapped to chromosome 2p24 and is frequently co-amplified with MYCN. Therefore, we performed genomic mapping with YACs to determine the physical relationship between DDX1 and MYCN, and whether DDX1 was contained within the core region of amplification. Based on YAC restriction mapping and content analysis, DDX1 maps 340 kb 5' of MYCN, outside the core domain of consistent amplification. Interestingly, we also determined by sequence analysis and detailed restriction mapping that G21, previously isolated as a 'neuroblastoma-specific' cDNA clone from an MYCN amplicon, is a partial cDNA of DDX1. Our data confirm that DDX1 is amplified in some but not all MYCN-amplified tumors, and that it is rearranged in other cases. This suggests that the co-amplification of DDX1 is due to its proximity to MYCN.

Original languageEnglish (US)
Pages (from-to)1561-1565
Number of pages5
JournalOncogene
Volume13
Issue number7
StatePublished - 1996
Externally publishedYes

Fingerprint

Restriction Mapping
Chromosome Mapping
Neuroblastoma
Complementary DNA
Gene Amplification
Sequence Analysis
Clone Cells
Chromosomes
Genes
Neoplasms
Proteins

Keywords

  • Amplification
  • DDX1
  • DEAD Box protein
  • MYCN
  • Neuroblastoma

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Kuroda, H., White, P. S., Sulman, E. P., Manohar, C. F., Reiter, J., Cohn, S. L., & Brodeur, G. M. (1996). Physical mapping of the DDX1 gene to 348 kb 5' of MYCN. Oncogene, 13(7), 1561-1565.

Physical mapping of the DDX1 gene to 348 kb 5' of MYCN. / Kuroda, Hiroshi; White, Peter S.; Sulman, Erik P.; Manohar, Chitra F.; Reiter, Jill; Cohn, Susan L.; Brodeur, Garrett M.

In: Oncogene, Vol. 13, No. 7, 1996, p. 1561-1565.

Research output: Contribution to journalArticle

Kuroda, H, White, PS, Sulman, EP, Manohar, CF, Reiter, J, Cohn, SL & Brodeur, GM 1996, 'Physical mapping of the DDX1 gene to 348 kb 5' of MYCN', Oncogene, vol. 13, no. 7, pp. 1561-1565.
Kuroda H, White PS, Sulman EP, Manohar CF, Reiter J, Cohn SL et al. Physical mapping of the DDX1 gene to 348 kb 5' of MYCN. Oncogene. 1996;13(7):1561-1565.
Kuroda, Hiroshi ; White, Peter S. ; Sulman, Erik P. ; Manohar, Chitra F. ; Reiter, Jill ; Cohn, Susan L. ; Brodeur, Garrett M. / Physical mapping of the DDX1 gene to 348 kb 5' of MYCN. In: Oncogene. 1996 ; Vol. 13, No. 7. pp. 1561-1565.
@article{47079b12e4ae490d99ce793570df1d99,
title = "Physical mapping of the DDX1 gene to 348 kb 5' of MYCN",
abstract = "One of the most important prognostic factors in neuroblastoma is amplification of the MYCN gene, which is strongly associated with advanced stages of disease and a poor prognosis. Although the MYCN amplicon sometimes spans more than 1 Mb, no other consistently expressed sequences from the MYCN amplicon have been reported. However, DDX1, a gene encoding a DEAD box: protein, was recently mapped to chromosome 2p24 and is frequently co-amplified with MYCN. Therefore, we performed genomic mapping with YACs to determine the physical relationship between DDX1 and MYCN, and whether DDX1 was contained within the core region of amplification. Based on YAC restriction mapping and content analysis, DDX1 maps 340 kb 5' of MYCN, outside the core domain of consistent amplification. Interestingly, we also determined by sequence analysis and detailed restriction mapping that G21, previously isolated as a 'neuroblastoma-specific' cDNA clone from an MYCN amplicon, is a partial cDNA of DDX1. Our data confirm that DDX1 is amplified in some but not all MYCN-amplified tumors, and that it is rearranged in other cases. This suggests that the co-amplification of DDX1 is due to its proximity to MYCN.",
keywords = "Amplification, DDX1, DEAD Box protein, MYCN, Neuroblastoma",
author = "Hiroshi Kuroda and White, {Peter S.} and Sulman, {Erik P.} and Manohar, {Chitra F.} and Jill Reiter and Cohn, {Susan L.} and Brodeur, {Garrett M.}",
year = "1996",
language = "English (US)",
volume = "13",
pages = "1561--1565",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Physical mapping of the DDX1 gene to 348 kb 5' of MYCN

AU - Kuroda, Hiroshi

AU - White, Peter S.

AU - Sulman, Erik P.

AU - Manohar, Chitra F.

AU - Reiter, Jill

AU - Cohn, Susan L.

AU - Brodeur, Garrett M.

PY - 1996

Y1 - 1996

N2 - One of the most important prognostic factors in neuroblastoma is amplification of the MYCN gene, which is strongly associated with advanced stages of disease and a poor prognosis. Although the MYCN amplicon sometimes spans more than 1 Mb, no other consistently expressed sequences from the MYCN amplicon have been reported. However, DDX1, a gene encoding a DEAD box: protein, was recently mapped to chromosome 2p24 and is frequently co-amplified with MYCN. Therefore, we performed genomic mapping with YACs to determine the physical relationship between DDX1 and MYCN, and whether DDX1 was contained within the core region of amplification. Based on YAC restriction mapping and content analysis, DDX1 maps 340 kb 5' of MYCN, outside the core domain of consistent amplification. Interestingly, we also determined by sequence analysis and detailed restriction mapping that G21, previously isolated as a 'neuroblastoma-specific' cDNA clone from an MYCN amplicon, is a partial cDNA of DDX1. Our data confirm that DDX1 is amplified in some but not all MYCN-amplified tumors, and that it is rearranged in other cases. This suggests that the co-amplification of DDX1 is due to its proximity to MYCN.

AB - One of the most important prognostic factors in neuroblastoma is amplification of the MYCN gene, which is strongly associated with advanced stages of disease and a poor prognosis. Although the MYCN amplicon sometimes spans more than 1 Mb, no other consistently expressed sequences from the MYCN amplicon have been reported. However, DDX1, a gene encoding a DEAD box: protein, was recently mapped to chromosome 2p24 and is frequently co-amplified with MYCN. Therefore, we performed genomic mapping with YACs to determine the physical relationship between DDX1 and MYCN, and whether DDX1 was contained within the core region of amplification. Based on YAC restriction mapping and content analysis, DDX1 maps 340 kb 5' of MYCN, outside the core domain of consistent amplification. Interestingly, we also determined by sequence analysis and detailed restriction mapping that G21, previously isolated as a 'neuroblastoma-specific' cDNA clone from an MYCN amplicon, is a partial cDNA of DDX1. Our data confirm that DDX1 is amplified in some but not all MYCN-amplified tumors, and that it is rearranged in other cases. This suggests that the co-amplification of DDX1 is due to its proximity to MYCN.

KW - Amplification

KW - DDX1

KW - DEAD Box protein

KW - MYCN

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=0029805635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029805635&partnerID=8YFLogxK

M3 - Article

C2 - 8875996

AN - SCOPUS:0029805635

VL - 13

SP - 1561

EP - 1565

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 7

ER -